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Abstract: Neurofibromatosis type 1 (NF1) is the most common autosomal dominant neurocutaneous syndrome with the 
estimated prevalence ranging from 1 in 3000 to 1 in 4000 individuals and wide phenotypical variability. NF1 is caused 
by autosomal dominant heterozygous mutations in the neurofibromin gene which is located on the chromosome 17 
(17q11.2). Phenotypically, NF1 patients have a very heterogeneous clinical phenotype. In this study, a novel frameshift 
NF1 variant was identified in a Croatian family with NF1 (mother and two daughters). The novel variant c. 
4482_4483delTA leads to sequence change that creates a premature translational stop signal (p.His1494Glnfs*7) in the 
NF1 gene. Our study showed that even when the same germline NF1 variant has been identified, there is still huge 
phenotypic variability in patients even within the same family, and it makes prognosis of the disease more complex. The 
development of next-generation sequencing technologies which allow rapid and accurate identification of disease-causing 
mutations becomes crucial for molecular characterization of NF1 patients as well as for patient follow-up, in the context 
of genetic counseling and clinical management of patients. 
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Neurofibromatosis type 1 (NF1) is the most common 
autosomal dominant neurocutaneous syndrome with the 
estimated prevalence ranging from 1 in 3000 to 1 in 
4000 individuals and wide phenotypical variability.1, 2 
Clinical diagnosis of NF1 is suspected with the 
appearance of the following major features: occurrence 
of café-au-lait macules, Lisch nodules of the iris, 
cutaneous and plexiform neurofibromas, axillary 
freckling and skeletal abnormalities.3 Phenotypically, 
NF1 patients have a very heterogeneous clinical 
phenotype. Besides skin lesions as the most noticeable 
manifestation, NF1 may affect many organs and cause 
psychiatric and psychological disorders.4, 5 
NF1 is caused by autosomal dominant heterozygous 
mutations in the neurofibromin gene which is located on 
the chromosome 17 (17q11.2). The NF1 gene is a tumor 
suppressor with the function of stimulating the GTPase 
activity of the RAS protein serving as a negative 
regulator of the cellular Ras/MAPK (mitogen-activated 
protein kinases) signaling pathway.6, 7 More than 3000 
different pathogenic allelic variants have been identified 
in the NF1 gene so far (The Human Gene Mutation 
Database), with half of the variants arising de novo, 
which is an expected observation since NF1 has one of 
the highest mutation rates reported in humans.8  
Molecular diagnosis in NF1 should be of great value for 
confirming the diagnosis. However, the large size of the 
gene (257 Kb), its high mutation rate, the existence of 
15 pseudogenes and no mutation hot-spots present a big 
challenge, and, therefore, molecular testing of the NF1 
gene is usually time-consuming and expensive.9-11 The 
development of next-generation sequencing (NGS) 
technologies which allows for rapid identification of 
disease-causing mutations and high-risk alleles has 
recently been introduced into NF1 diagnosis.12-15 
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MATERIAL AND METHODS 
Study subjects, disease criteria, and clinical evaluation 
A family (mother and two daughters) with unusual 
clinical presentations of NF1 were recruited at the 
Clinical Hospital Center Zagreb for diagnostic analysis 
of the NF1 gene (Figure 1). The NF1 diagnosis was 
established based on the diagnostic criteria of the 
National Institutes of Health consensus statement.16 
Peripheral blood specimens were collected from the 
patients. Clinical data including available medical 
histories, imaging, and histopathological examinations 
were obtained. The study was carried out in accordance 
with the principles of the Declaration of Helsinki. 





Figure 1. Pedigree of the family. 
Legend: Squares indicate males, circles indicate females, respectively; 




Targeted gene enrichment and high-throughput 
sequencing 
The gene panel was designed using the Design Studio 
Tool (Illumina, San Diego, CA, USA). The coding 
regions of 142 genes were selected for targeted gene 
enrichment. The coordinates of genomic regions were 
based on NCBI build 37 (UCSC hg19). Total DNA was 
extracted from peripheral blood samples using the Zymo 
Universal DNA kit (ZR; Zymo Research) according to 
the manufacturer’s instructions. The DNA concentration 
of each sample was determined using a Qubit 3 
Fluorimeter and the dsDNA HS kit (Invitrogen, Thermo 
Scientific, Wilmington, DE, USA). Custom targeted 
gene enrichment and DNA library preparation were 
performed using the Nextera Rapid Capture Custom 
Enrichment kit (Illumina) according to the 
manufacturer’s instructions. The targeted regions were 
sequenced using the Illumina MiSeq platform, 
generating approximately 14 million of 150-bp paired-
end reads for each sample (Q30 ≥90%). 
 
 
Variant calling, filtering, and classification 
The FASTQ files generated by the MiSeq were streamed 
to Illumina BaseSpace where the data was assembled 
with the BWA Genome Alignment Software and the 
variants called according to the GATK Variant Caller. 
This produced a Variant Call Format (.VCF) file, which 
was further imported into Illumina Variant Interpreter. 
Variants were considered disease-causing under strict 
criteria in accordance with the published Sherloc 
guidelines for the interpretation of sequence variants. 
After sequencing data submission, the pipeline executed 
the following steps: the quality checks and filter of the 
reads; the alignment on the reference genome hg19; 
variant preprocessing; coverage statistics and metrics; 
variant calling; variant annotation. Genetic variants 
predicted to alter the protein, such as non-synonymous 
variants, nonsense variants, canonical splicing site 
variants (affecting the donor or acceptor splice sites), in-
frame and frameshift insertion/deletions were selected. 
To assess the potential functional impacts of variants, 
two bioinformatics algorithms were used: Sorting 
Intolerant From Tolerant (SIFT) and Mutation Taster. 
Using the online multiple protein sequence alignment 
tool COBALT we analyzed the conserved domain 
among Homo sapiens (human), Rattus norvegicus 
(Norway rat) and Mus musculus (mouse) to see whether 
the NF1 mutation was located in the conserved region of 
the human NF1 protein. 
 
 
Variant databases and prediction programs  
The list of variant databases and prediction programs 
used in the study is presented in Table 1.  
 
 
Table 1. List of variant databases and prediction programs 
Variant databases: 
 
































Our first patient is a woman with positive diagnostic 
criteria for NF1. Her two daughters that we also describe 
later in the text have positive diagnostic criteria for NF1. 
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Family history is positive for NF1 (her mother and 
grandfather had numerous café-au-lait spots and 
cutaneous neurofibromas). At the age of 45, she was 
admitted to hospital because of a large tumorous mass 
on the right side of the head and neck. Besides a large, 
hard and elastic subcutaneous tumor mass on the right 
side of the head and neck, physical examination revealed 
numerous cafée au lait spots, cutaneous and 
subcutaneous neurofibromas and axillary freckling. 
Large (around 5 cm in diameter), well-circumscribed 
spherical tumorous mass, located between the internal 
carotid artery and the internal jugular vein, reaching the 
jugular foramen in the cranial direction was found 
intraoperatively. It was hardly detachable from the vagal 
nerve. Pathohistological examination revealed an 
encapsuled tumorous mass, 5.5x4x3.5 cm in diameter, 
histologically consisting of multiplied stromal cells, 
elongated and spindle-shaped, moderately polymorphic, 
with a few areas of high cellularity. Some cells that 
resembled ganglionic cells were also present. The tumor 
stroma was abundant and collagenous. Some areas 
showed the presence of cartilage tissue and necrosis. 
Immunohistochemical staining showed focal S-100 
positivity. Diagnosis of malignant peripheral sheath 
tumor was established. Radiation therapy was 
administered postoperatively. Positron emission 
tomography scan performed 4 months postoperatively 
showed no signs of tumor dissemination. A brain MRI 
performed 1 year postoperatively revealed focal areas of 
signal intensity (FASI) in the anteromedial part of right 
thalamic nuclei, splenium of corpus callosum and 
bilaterally in both dentate nuclei of the cerebellum - all 
lesions typically found in NF1 patients. Currently, the 
patient is followed up regularly and she is without signs 
of tumor relapse.  
The second patient is the older daughter with positive 
diagnostic criteria for NF1, delayed psychomotor 
development and suspected convulsions. She was born 
from an unremarkable pregnancy and labor. The 
pediatrician   noticed    some   hypotonia   and   delayed  
psychomotor development in the infancy period and 
later. Language development was markedly delayed. In 
infancy she had several episodes of generalized 
convulsions that resembled affective crises and the EEG 
was repeatedly normal. A brain MRI was performed at 
the age of 12; it revealed FASI bilaterally in both dentate 
nuclei of cerebellum. At the age of 13 she was diagnosed 
with thoracic kyphoscoliosis. The MRI of thoracic spine 
revealed dural ectasia at the level of anterior coalition of 
the body of the 6th and 7th thoracic vertebra with 
hypoplastic intervertebral discus and arcuate kyphosis. 
Ophthalmologic examination revealed multiple Lisch 
nodules of the iris. Physical examination performed at 
the age of 13 showed short stature (3rd centile), 
sinistroconvex kyphoscoliosis of thoracic spine, café au 
lait spots on the front and back of the chest and several 
subcutaneous neurofibromas. Signs of mild cognitive 
impairment were also present. 
The third patient is the younger daughter with positive 
diagnostic criteria for NF1 and very rare presentation of  
 
Figure 2. Magnetic angiography in the younger daughter: 
magnetic angiography showed left frontal, temporal and parietal pial 
angiomatosis and a hypoplastic spheroidal and opercular segment of 
the left middle cerebral artery (MCA), with many collaterals of 





Figure 3. Digital subtraction angiography: 
DSA showed bilateral stenosis of the internal carotid artery. 
Catheterization of the right common carotid artery and right inner 
carotid artery in the younger daughter showed terminal part stenosis 
of the right inner carotid artery (ICA) immediately before bifurcation 
(arrow); Filiform filling of the residual part of the right inner carotid 
artery lumen with a weaker filling of the distal segments of the 
circulation, i.e. right middle cerebral artery and right (MCA) and 
anterior cerebral artery (ACA). 
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NF1, moyamoya syndrome (MMS). She was born form 
an uneventful pregnancy and labor. Her mother noticed 
café au lait spots already in the infancy period. Her 
psychomotor development was moderately delayed, 
especially in the domain of cognitive and language 
development. At the age of 3, she experienced the first 
episode of epileptic seizures and she was given valproate 
as an antiepileptic drug. At the age of 4, she was 
diagnosed with occlusive cerebral angiopathy; MMS of 
the left internal carotid artery, middle cerebral artery, 
right internal carotid artery, right anterior and middle 
cerebral artery (Figure 2, Figure 3). Soon after the 
diagnosis, she experienced a transitory ischemic attack 
with left hemisyndrome, and she was neurosurgicaly 
treated in the foreign center (direct and indirect 
revascularization of affected blood vessels). After the 
operation her clinical state is stable, without new deficits 
in neurological examination and new epileptic attacks. 
Her school performance is very poor and there are signs 
of low moderate cognitive impairment.  
Physical examination at the age of 10 revealed short 
stature (3rd centile), numerous café au lait spots, several 
subcutaneous neurofibromas and signs of moderate 




Targeted sequencing of the three probands generated a 
mean of 14 million total effective reads, with an average 
of 99.88% mapping to the reference genome. The 
average sequencing depth on the target sequence region 
per individual was tenfold. 230 SNPs and 2 InDels were 
detected in the proband 1, 234 SNPs and 2 InDels were 
detected in the proband 2, 231 SNPs and 3 InDels were 
detected in the proband 3. Commonly known variants, 
documented in the 1000 Genomes Project, dbSNP, 
NHLBI ESP6500 along with synonymous variants, were 
removed in order to find the candidate disease-causing 
variants. In silico programs were employed to predict 
the possible effects of nonsynonymous variants on 
protein functions. A heterozygous frameshift variant 
c.4482_4483delTA (p.His1494GlnfsTer7) in the NF1 
gene was selected as a potential disease-causing variant 
for the probands of pedigree 1,2 and 3. Predicted 
pathogenicity analyses performed by different in silico 
programs (MutationTaster and SIFT) indicated that this 
variant was deleterious. After aligning the three protein 
sequences for the conserved region, this shared NF1 
frameshift mutation was discovered to be located in a 




In this study, a novel frameshift NF1 variant was 
identified in a Croatian family with NF1 (a mother and 
two daughters). The novel variant c. 4482_4483delTA 
leads to sequence change that creates a premature 
translational stop signal (p.His1494Glnfs*7) in the NF1 
gene. This variant is not present in population databases 
(ExAC no frequency). Loss-of-function variants in NF1 
are known to be pathogenic.17, 18 Multiple sequence 
alignment programs showed that the residue p.His1494 
is phylogenetically conserved, and in silico programs 
indicated that they are damaging. 
The variant is located in the GTPase-activating protein-
related domain (GRD) of the protein, the best 
characterized functional domain of neurofibromin. 
Several studies  have shown that the GRD domain has 
Ras-GAP activity both in vitro and in vivo.19 Current 
data suggest that about 30–65% of patients with NF1 
have specific learning deficits.20 Although a direct 
correlation between specific mutations in NF1 and 
phenotypes has not been established, missense mutation 
that disrupts the Ras-GAP function of NF1 was found in 
patients with multiple symptoms including learning 
disability and cognitive impairment.21 In general, in  
most NF1 patients with learning difficulties global 
cognitive impairment is not a very common feature.22 
Although carrying the same variant, our three patients 
show a range from normal cognitive function in the 
mother and mild cognitive impairment in the older 
daughter to moderate cognitive impairment in the 
younger daughter. 
Only a few NF1 genotype-phenotype correlations have 
been identified due to its wide phenotypic diversity and 
the extreme variability of the mutation spectrum. The 
clearest genotype-phenotype correlation show gross 
constitutional deletions of the NF1 gene associated with 
a severe form of the disease and  increased susceptibility 
to malignant peripheral nerve sheath tumors 
(MPNST).23, 24 It was recently shown that patients with 
missense mutations in codons 844-848 have a high 




Figure 4. Location of the frameshift variant detected in mother and two daughters. 
The mutated site was referred against NF1 or NF1 homolog gene from Homo sapiens (P21359.2), Rattus norvegicus (P97526.1) and Mus musculus 
(Q04690.1). The position of the frameshift mutation marked by an arrow; black letters show altered amino acids caused by the frameshift variant. 
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and symptomatic spinal neurofibromas, symptomatic 
optic pathway gliomas, other malignant neoplasms, as 
well as bone abnormalities.25 Patients with deletion of 
Met 992 or missense mutation of Arg 1809 lack 
plexiform or cutaneous neurofibromas making these two 
germline mutations associated with milder disease 
outcomes in NF1.26-28 Our patients showed intrafamilial 
phenotype variability: mother with rare malignant 
peripheral sheath tumor, older daughter with usual 
clinical presentation and younger daughter with very 
rare MMS and early severe presentation. This suggests 
that NF1 clinical phenotypes may be influenced not only 
by NF1 variants, but also by other factors, including 
second hit mutations, mosaicism, genetic modifiers, 
epigenetic and environmental factors.27, 29, 30 Studies of 
twins with NF1 have revealed that each major symptom 
associated with NF1 is likely to be affected by distinct 
genetic modifiers.31 
In our first patient (the mother), diagnosis of MPNST 
was established. MPNST are biologically aggressive 
soft tissue sarcomas that are challenging to treat 
effectively. About 10% of NF1 patients develop 
MPNST, and it is known that this type of tumors have 
high metastatic potential and poor prognosis.32, 33 Large 
tumor size at presentation (typically >5 cm) has been the 
most consistently determined adverse prognostic 
factor.34 Early diagnosis and surgery offer the most 
efficiency in treatment so far, chemotherapy and 
radiotherapy show no clear benefits for patient survival. 
Currently our patient is followed up regularly and she is 
without signs of tumor relapse. Discovery of the 
biomarkers for early detection of MPNSTs would be of 
great importance. As seen in our case presentation, it is 
hard to predict whether two daughters have a higher risk 
of developing MPNST. Besides biomarkers for early 
detection, patients with MPNSTs would benefit from 
accurate molecular prognostics markers. Study from 
Zou and colleagues showed that the expression level of 
p53 was significantly associated with a worse 
outcome.35 Another study detected the AKT and TOR 
pathway, activated in a broad range of malignancies 
including sarcoma, with a negative prognosis proposing 
the inhibition of mTOR as a potential treatment target 
for both NF1-related and sporadic MPNSTs.36 MET 
activation has been suggested as a molecular marker of 
inferior prognosis which is in line with data showing that 
MET targeting inhibits invasive phenotype of MPNST 
cells both in vitro and in vivo.37 
MMS is a rare cerebrovascular disorder developing by 
stenosis and occlusion of small anastomotic vessels in 
the distal branches of bilateral internal carotid arteries. 
MMS occurs in 2.3-6% of children with NF1. 
Symptoms include neurological findings such as 
epileptic seizures, headache, paresthesia, dysphasia, 
nystagmus, aphasia, and borderline mental level.35, 36 
There are certain evidence indicating that MMS is 
related to genetic factors in familial cases, although the 
involvement of the NF1 gene in the occurrence of MMS 
remains controversial.37 NF1 and MMS could be 
associated by close proximity of the responsible genes 
on chromosome 17.38 Our patient was diagnosed with 
MMS at the age 4, which is slightly earlier then observed 
in previous patients (mean age between 5.2 and 11.4 
years). Apart from NF1, MMS is rarely observed in 
connection with other RASopathies. There is only one 
report on the genetic background of patients with NF1 
showing no correlation between the NF1 genotype and 
MMS phenotype.39  
In conclusion, we identified a novel frameshift variant c. 
4482_4483delTA in the NF1 gene in a mother and two 
daughters. Our study showed that even when the same 
germline NF1 variant has been identified, there is still 
huge phenotypic variability in patients, and it makes 
prognosis on the disease more complex. The 
development of next-generation sequencing 
technologies which allow rapid and accurate 
identification of disease-causing mutations becomes 
crucial for molecular characterization of NF1 patients as 
well as for patient follow-up in the context of genetic 
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